Cellectis SA (CLLS, Financial), a pioneer in gene-editing technology, is generating excitement on Wall Street, as analysts believe there is about 400% upside potential over its current prices. The current price is only $1.41 per share, and this under-the-radar cancer therapy has caught the eye of eight analysts who average a price target of $7.00 with a range of estimates from $3.00 to a really bullish $11.00. The company is working on the TALEN- TALEN-based gene Editing and is developing its pipeline
Key indications in the allogeneic CAR-T portfolio are UCART22, which UCART20x22 will support for the treatment of B-cell acute lymphoblastic leukemia and non-Hodgkin lymphomas, respectively. They have designed these therapies to be off-the-shelf solutions, seriously advancing the field of reducing the cost and complexity involved with cell therapy.
To continue investing in their pipeline, Cellectis has engaged with AstraZeneca to deliver cell and innovative gene therapies. This agreement signified a strong technology prowess for the company to make discovery-aided breakthroughs in genetic research and treatment solutions.
Analysts are optimistic due to the strategic positioning of Cellectis in the flourishing category of personalized medicine, which is rapidly gaining greater relevance in the global health landscape. Yet, like most penny stocks, such investment comes with certain risks using regulatory hurdles and clinical outcomes on successful trials.
For risk-savvy investors, Cellectis is a high-stakes gamble in the gene-editing arena. As this develops and merges further in partnerships, the company might become very well positioned to revolutionize treatment for cancers and make its current valuation look like a bargain in the years ahead.
